Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in adults with type 1 diabetes and obesity or overweight
NCT06962280Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2025
- Primary completion
- Nov 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of tirzepatide in type 1 diabetes mellitus (T1D), sponsored by Eli Lilly and Company. Primary endpoint: Change from Baseline in Hemoglobin A1c at 40 weeks. Started May 2025; status: active, not recruiting.
02
Drugs
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06962280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06962280.